At final analysis of the core study ( data cutoff , October , @ ) , @-year progression-free survival was higher in the imatinib group ( @ % -LSB- @ % CI @-@ -RSB- ) than in the nilotinib group ( @ % -LSB- @-@ -RSB- ; hazard ratio @ -LSB- @ % CI @-@ -RSB- ) .